Investing in China's Pharmaceutical Industry - 2nd Edition

Investing in Chinas Pharmaceutical Industry - 2nd Edition
Download Investing in China's Pharmaceutical Industry - 2nd Edition (959kb) - English version

Download Investing in China's Pharmaceutical Industry - 2nd Edition (1.3mb) - Chinese version

Download Investing in China's Pharmaceutical Industry - 2nd Edition (288kb) - PowerPoint executive summary presentation
Investing in China’s Pharmaceutical Industry is the second edition of a paper published by PwC looking into the current pharmaceutical market conditions in China. The report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical (pharma) industry in China. This publication builds on the foundation set in the first report, published in 2006. The pharmaceutical/ life sciences landscape is changing fast in China and this new edition reviews, updates and expands on the following key areas: Traditional Chinese Medicine (TCM), China's OTC Market, Medical Devices, CROs and CMOs, Development of Innovation, Tax Incentives in China, Bribery & Corruption in Sales and Marketing, Challenge of Drug Pricing, Distribution Systems, Intellectual Property Protection, Market Consolidation and Financial Impacts of Investments.